statistiche ricercatore

Continente	#
NA - Nord America	621
AS - Asia	271
EU - Europa	253
SA - Sud America	40
Continente sconosciuto - Info sul continente non disponibili	37
AF - Africa	26
Totale	1.248

Nazione	#
US - Stati Uniti d'America	597
SG - Singapore	121
IT - Italia	84
CN - Cina	59
RU - Federazione Russa	45
SE - Svezia	33
HK - Hong Kong	27
BR - Brasile	25
CA - Canada	19
GB - Regno Unito	19
DE - Germania	17
VN - Vietnam	16
CI - Costa d'Avorio	14
FR - Francia	13
FI - Finlandia	12
BD - Bangladesh	10
IN - India	8
BE - Belgio	7
IQ - Iraq	6
AR - Argentina	5
NL - Olanda	5
VE - Venezuela	5
JP - Giappone	4
AT - Austria	3
CO - Colombia	3
ID - Indonesia	3
LT - Lituania	3
PL - Polonia	3
TR - Turchia	3
ZA - Sudafrica	3
CZ - Repubblica Ceca	2
EG - Egitto	2
ES - Italia	2
KE - Kenya	2
KW - Kuwait	2
MX - Messico	2
MY - Malesia	2
PH - Filippine	2
RO - Romania	2
TN - Tunisia	2
UZ - Uzbekistan	2
AL - Albania	1
BJ - Benin	1
DZ - Algeria	1
EC - Ecuador	1
GE - Georgia	1
JM - Giamaica	1
KG - Kirghizistan	1
ME - Montenegro	1
NI - Nicaragua	1
NP - Nepal	1
OM - Oman	1
PA - Panama	1
PK - Pakistan	1
SA - Arabia Saudita	1
SN - Senegal	1
SR - Suriname	1
SX - ???statistics.table.value.countryCode.SX???	1
UA - Ucraina	1
Totale	1.212

Nome	#
Multiple Sclerosis Progression and Relapse Activity in Children	147
Disease-modifying drugs can reduce disability progression in relapsing multiple sclerosis	137
Characterization of the rs2802292 SNP identifies FOXO3A as a modifier locus predicting cancer risk in patients with PJS and PHTS hamartomatous polyposis syndromes	124
Low versus high dose erythropoiesis-stimulating agents in hemodialysis patients with anemia: A randomized clinical trial	122
Metformin Therapy and Risk of Cancer in Patients with Type 2 Diabetes: Systematic Review	121
Disease-Modifying Treatments and Time to Loss of Ambulatory Function in Patients With Primary Progressive Multiple Sclerosis	100
Big Multiple Sclerosis Data network: an international registry research network	86
The prevalence and correlates of low sexual functioning in women on hemodialysis: A multinational, cross-sectional study	77
Towards a validated definition of the clinical transition to secondary progressive multiple sclerosis: A study from the Italian MS Register	77
Evaluation of drivers of treatment switch in relapsing multiple sclerosis: a study from the Italian MS Registry	74
null	63
null	39
null	32
Early Intensive Versus Escalation Approach: Ten‐Year Impact on Disability in Relapsing Multiple Sclerosis	27
Proteinuria remission and long-term kidney outcome in children with IgA nephropathy	22
Totale	1.248

	Totale	Lug	Ago	Sett	Ott	Nov	Dic	Gen	Feb	Mar	Apr	Mag	Giu
2021/2022	48	0	0	0	1	3	8	2	3	4	6	6	15
2022/2023	114	13	16	9	11	11	16	1	17	14	1	5	0
2023/2024	51	4	6	3	4	6	11	0	6	1	3	0	7
2024/2025	217	11	4	5	12	5	20	14	35	13	16	24	58
2025/2026	572	74	19	42	69	100	38	53	18	50	50	14	45
2026/2027	104	22	19	22	41	0	0	0	0	0	0	0	0
Totale													1.248